Generex Biotechnology Corporation
GNBT · OTC
7/31/2020 | 7/31/2019 | 7/31/2018 | 7/31/2017 | |
|---|---|---|---|---|
| Revenue | $2,661 | $6,204 | $703 | $0 |
| % Growth | -57.1% | 782.2% | – | – |
| Cost of Goods Sold | $580 | $4,138 | $0 | $0 |
| Gross Profit | $2,082 | $2,065 | $703 | $0 |
| % Margin | 78.2% | 33.3% | 100% | – |
| R&D Expenses | $2,106 | $1,749 | $839 | $422 |
| G&A Expenses | $17,898 | $21,409 | $2,360 | $1,175 |
| SG&A Expenses | $17,898 | $21,409 | $2,360 | $1,175 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$185 | $0 | $0 | $0 |
| Operating Expenses | $19,820 | $23,158 | $3,199 | $1,597 |
| Operating Income | -$17,923 | -$21,093,002 | -$2,496 | -$1,597 |
| % Margin | -673.5% | -339,990.4% | -354.9% | – |
| Other Income/Exp. Net | -$16,309 | $19,427,615 | $38,444 | -$75,236 |
| Pre-Tax Income | -$34,232 | -$11,007 | $35,949 | -$76,833 |
| Tax Expense | -$9,191 | $20,426 | $39,028 | -$74,493 |
| Net Income | -$33,335 | -$9,341 | $36,334 | -$70,016 |
| % Margin | -1,252.7% | -150.6% | 5,166.6% | – |
| EPS | -0.46 | -0.14 | 0.67 | -2.41 |
| % Growth | -228.6% | -120.9% | 127.8% | – |
| EPS Diluted | -0.46 | -0.14 | 14.02 | -2.41 |
| Weighted Avg Shares Out | 73,113 | 67,704 | 53,991 | 29,026 |
| Weighted Avg Shares Out Dil | 73,113 | 67,704 | 2,591 | 29,026 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $48 | $0 | $0 |
| Interest Expense | $7,104 | $7,088 | $584 | $743 |
| Depreciation & Amortization | $1,004 | $426 | $24 | $5 |
| EBITDA | -$26,110 | -$21,072,150 | $36,941 | -$69,268 |
| % Margin | -981.2% | -339,654.2% | 5,252.9% | – |